MIRCERA
Mode of Action
Through its different receptor interaction and longer half-life – delivers sustained anaemia management.
MIRCERA is a continuous erythropoietin receptor activator with a different receptor-binding activity to other erythropoiesis-stimulating agents (ESAs). MIRCERA enables continuous stimulation of the erythropoietin receptor which allows maintenance of stable Hb levels in the target range.1,2
MIRCERA has the longest half-life of all ESAs; up to six times longer than darbepoetin alfa and up to 27 times longer than epoetin alfa (see Figure).3-7 The extended half-life allows more sustained activation of erythropoietin receptor compared with epoetin beta.1
Half-life of erythropoiesis-stimulating agents.3-7
Learn more detailed information by visiting www.mircera.com
References:
1.Haselbeck A, Reigner B, Jordan P, et al. Pre-clinical and phase I pharmacokinetic and mode-of-action studies of CERA (Continuous Erythropoietin Receptor Activator), an innovative erythropoietic agent with an extended serum half-life. Proc Am Soc Clin Oncol. 2003;22:748 (abstract 3006).
2.Sulowicz W, Locatelli F, Ryckelynck J-P, et al. Once-monthly subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) maintains stable control in patients with chronic kidney disease on dialysis directly converted from epoetin one to three times weekly. Clin J Amer Soc Nephrol. 2007 doi:10.2215/CJN.03631006.
3.Aranesp® Summary of Product Characteristics. Amgen. 2006.
4.MIRCERA Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.
5.Eprex® Summary of Product Characteristics. Janssen-Cilag Ltd. 2006.
6.NeoRecormon® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.
7.Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006 doi:10.2215/CJN.0073030
